The Manufacturers Life Insurance Company Takes Position in Immunome, Inc. $IMNM

The Manufacturers Life Insurance Company bought a new stake in shares of Immunome, Inc. (NASDAQ:IMNM) during the 2nd quarter, according to its most recent filing with the SEC. The firm bought 172,893 shares of the company’s stock, valued at approximately $3,664,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Allworth Financial LP purchased a new position in Immunome in the 2nd quarter worth approximately $25,000. KBC Group NV purchased a new stake in shares of Immunome during the first quarter valued at approximately $60,000. BNP Paribas Financial Markets lifted its position in shares of Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after purchasing an additional 2,909 shares in the last quarter. Strs Ohio acquired a new position in shares of Immunome during the fourth quarter worth $64,000. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Immunome by 121.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock valued at $65,000 after purchasing an additional 3,802 shares during the period. 44.58% of the stock is owned by institutional investors and hedge funds.

Immunome Stock Down 1.2%

Shares of NASDAQ IMNM opened at $27.07 on Wednesday. The firm’s 50-day moving average price is $24.52 and its two-hundred day moving average price is $22.48. Immunome, Inc. has a 52-week low of $8.66 and a 52-week high of $30.06. The stock has a market capitalization of $3.07 billion, a P/E ratio of -10.70 and a beta of 2.13.

Immunome (NASDAQ:IMNM) last posted its earnings results on Tuesday, August 11th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.14). As a group, equities research analysts expect that Immunome, Inc. will post -2.38 earnings per share for the current year.

Insider Buying and Selling

In other Immunome news, insider Kinney Horn sold 90,616 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $25.09, for a total value of $2,273,555.44. Following the sale, the insider directly owned 50,366 shares of the company’s stock, valued at $1,263,682.94. This trade represents a 64.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Isaac Barchas sold 11,048 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $27.25, for a total value of $301,058.00. Following the completion of the sale, the director owned 92,211 shares in the company, valued at $2,512,749.75. The trade was a 10.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 682,310 shares of company stock valued at $15,675,566. Insiders own 7.21% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Leerink Partners decreased their price objective on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research report on Friday, May 15th. Wall Street Zen lowered Immunome from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Citigroup reiterated a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Finally, Truist Financial raised their price objective on Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Twelve research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $34.64.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.